Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Extrawell Pharmaceutical Holdings 3-Year ROIIC %?
Extrawell Pharmaceutical HoldingsHKSE:00858 -1.19% 3-Year ROIIC % is -0.20 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 946 Drug Manufacturers companies, Extrawell Pharmaceutical Holdings ranks worse than 56.77% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Extrawell Pharmaceutical Holdings does not have enough data to calculate 3-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Extrawell Pharmaceutical Holdings 3-Year ROIIC % Related Terms
Extrawell Pharmaceutical Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extrawell Pharmaceutical Holdings 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Extrawell Pharmaceutical Holdings's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( (Mar. 2026) - (Mar. 2023) )
/
( (Mar. 2026) - (Mar. 2023) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Extrawell Pharmaceutical Holdings (HKSE:00858) has a 3-Year ROIIC % of -0.20 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Extrawell Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #537 out of 946 companies in the Drug Manufacturers industry, placing it in the top 56.8%.
Is Extrawell Pharmaceutical Holdings' 3-Year ROIIC % too high?
Extrawell Pharmaceutical Holdings' current 3-Year ROIIC % is -0.20. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #537 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Extrawell Pharmaceutical Holdings' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #537 out of 946 companies for 3-Year ROIIC %. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median 3-Year ROIIC % is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current 3-Year ROIIC % is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 66% above its estimated fair value. The current 3-Year ROIIC % is -0.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current 3-Year ROIIC % is -0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00858 has been successfully added to your 
